Veterinary and human vaccine evaluation methods

Proceedings of the Royal Society B: Biological Sciences

Volumn 281, Issue 1784, 2014, Pages

  Knight Jones, T J D ^a,b   Edmond, K ^c   Gubbins, S ^a   Paton, D J ^a  

^a INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Evaluation; Vaccine; Vaccine effectiveness; Veterinary

Indexed keywords

BACTERIAL POLYSACCHARIDE; EPSI POLYSACCHARIDE;

FOOT AND MOUTH DISEASE; VACCINE;

BIOLOGICAL MODEL; CHEMOTAXIS; ENTROPY; GENETICS; KINETICS; METABOLISM; MOVEMENT (PHYSIOLOGY); OSMOTIC PRESSURE; PHYSIOLOGY; QUORUM SENSING; SINORHIZOBIUM MELILOTI;

CHEMOTAXIS; ENTROPY; GENETICS; KINETICS; METABOLISM; MODELS, BIOLOGICAL; MOVEMENT; OSMOTIC PRESSURE; PHYSIOLOGY; POLYSACCHARIDES, BACTERIAL; QUORUM SENSING; SINORHIZOBIUM MELILOTI;

EID: 84898606383     PISSN: 09628452     EISSN: 14712954     Source Type: Journal    
DOI: 10.1098/rspb.2013.2839     Document Type: Review

References (53)

1. Plotkin SA, Orenstein WA, Offit PA. (eds) 2008 Vaccines, 5th edn. Philadelphia, PA: Saunders.
2. Van Aarle P. 2010 Immunological correlates of vaccine-derived protection against FMD: the regulatory perspective. In Vaccine efficacy: immunological correlates of vaccine derived protection, Fondation Merieux, Veyrier-du-Lac, France, 20-22 September 2010.
3. Knight-Jones TJ, Rushton J. 2013 The economic impacts of foot and mouth disease-what are they, how big are they and where do they occur? Prev. Vet. Med. 112, 161-173. (doi:10.1016/j.prevetmed.2013.07.013)
4. Meeusen ENT, Walker J, Peters A, Pastoret P-P, Jungersen G. 2007 Current status of veterinary vaccines. Clin. Microbiol. Rev. 20, 489-510. (doi:10. 1128/cmr.00005-07)
5. OIE. 2012 Manual of diagnostic tests and vaccines for terrestrial animals 2012. Paris: World Organisation for Animal Health.
6. Halloran ME, Longini IM, Struchiner CJ. 2009 Design and analysis of vaccine studies. New York, NY: Springer.
7. Pastoret P-P. 1997 Veterinary vaccinology. Amsterdam, The Netherlands: Elsevier.
8. Parida S. 2009 Vaccination against foot-and-mouth disease virus: strategies and effectiveness. Expert Rev. Vaccines 8, 347-365. (doi:10.1586/14760584. 8.3.347)
9. Plotkin SA. 2008 Vaccines: correlates of vaccineinduced immunity. Clin. Infect Dis. 47, 401-409. (doi:10.1086/589862)
10. Nguipdop-Djomo P, Thomas SL, Fine PEM. 2013 Correlates of vaccine-induced protection: methods and implications. WHO/IVB/10.00, 181. See http:// apps.who.int/iris/bitstream/10665/84288/1/ WHO_IVB_13.01_eng.pdf.
11. Hu RL, Fooks AR, Zhang SF, Liu Y, Zhang F. 2008 Inferior rabies vaccine quality and low immunization coverage in dogs (Canis familiaris) in China. Epidemiol. Infect. 136, 1556-1563. (doi:10.1017/ s0950268807000131)
12. Chen RT, Orenstein WA. 1996 Epidemiologic methods in immunization programs. Epidemiol. Rev. 18, 99-117. (doi:10.1093/oxfordjournals.epirev.a017931)
13. Millar EV, Watt JP, Bronsdon MA, Dallas J, Reid R, Santosham M, O'Brien KL. 2008 Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin. Infect. Dis. 47, 989-996. (doi:10.1086/591966)
14. European Medicines Agency. 2003 Committee for veterinary medicinal products: revised position paper on indications for veterinary vaccines-EMEA/ CVMP/042/97-Rev.1-FINAL.
15. USDA. 2011 Veterinary Services Memorandum NO. 800.50. Animal and Plant Health Inspection Service, Washington, DC, USA.
16. European pharmacopoeia. 2012 Evaluation of efficacy of veterinary vaccines and immunosera. Ch. 5.2.7, 8th edn, Version 8.2.
17. Council Directive. 2001 2001/82/EC-Directive 2001/ 82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products (Official Journal L 311, 28/11/2001 p. 1-66).
18. Hope T, McMillan J. 2004 Challenge studies of human volunteers: ethical issues. J. Med. Ethics 30, 110-116. (doi:10.1136/jme.2003.004440)
19. Henry JL, Jaikaran ES, Davies JR, Tomlinson AJ, Mason PJ, Barnes JM, Beale AJ. 1966 A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J. Hyg. (Lond) 64, 105-120. (doi:10.1017/S0022172400040389)
20. Bonell CP, Hargreaves J, Cousens S, Ross D, Hayes R, Petticrew M, Kirkwood BR. 2011 Alternatives to randomisation in the evaluation of public health interventions: design challenges and solutions. J. Epidemiol. Community Health 65, 582-587. (doi:10.1136/jech.2008.082602)
21. European Medicines Agency. 2001 Committee for veterinary medicinal products: note for guidance field trials with veterinary vaccines. EMEA/CVMP/ 852/99-FINAL.
22. Clemens J, Brenner R, Rao M, Tafari N, Lowe C. 1996 Evaluating new vaccines for developing countries. Efficacy or effectiveness? JAMA 275, 390-397. (doi:10. 1001/jama.1996.03530290060038)
23. Orenstein WA, Bernier RH, Hinman AR. 1988 Assessing vaccine efficacy in the field. Further observations. Epidemiol. Rev. 10, 212-241.
24. Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ, Sirotkin B. 1985 Field evaluation of vaccine efficacy. Bull. World Health Organ. 63, 1055-1068.
25. Hogerwerf L. 2011 Reduction of Coxiella burnetii prevalence by vaccination of goats and sheep, the Netherlands. Emerg. Infect. Dis. 17, 379-386. (doi:10.3201/eid1703.101157)
26. Knight-Jones TJ, Bulut AN, Gubbins S, Stark KD, Pfeiffer DU, Sumption KJ, Paton DJ. 2014 Retrospective evaluation of foot-and-mouth disease vaccine effectiveness in Turkey. Vaccine 32, 1848-1855. (doi:10.1016/j.vaccine.2014.01.071)
27. Fine PE, Ponnighaus JM, Maine N, Clarkson JA, Bliss L. 1986 Protective efficacy of BCG against leprosy in Northern Malawi. Lancet 2, 499-502. (doi:10.1016/ S0140-6736(86)90367-3)
28. Marin M, Nguyen HQ, Langidrik JR, Edwards R, Briand K, Papania MJ, Seward JF, LeBaron CW. 2006 Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. Clin. Infect. Dis. 42, 315-319. (doi:10.1086/498902)
29. Leval A et al. 2013 Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J. Natl Cancer Inst. 105, 469-474. (doi:10.1093/jnci/djt032)
30. Grassly NC, Wenger J, Durrani S, Bahl S, Deshpande JM, Sutter RW, Heymann DL, Aylward RB. 2007 Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 369, 1356-1362. (doi:10.1016/s0140-6736(07) 60531-5)
31. O'Loughlin RE, Edmond K, Mangtani P, Cohen AL, Shetty S, Hajjeh R, Mulholland K. 2010 Methodology and measurement of the effectiveness of Haemophilus influenzae type b vaccine: systematic review. Vaccine 28, 6128-6136. (doi:10. 1016/j.vaccine.2010.06.107)
32. Feikin DR, Scott JA, Gessner BD. 2014 Use of vaccines as probes to define disease burden. Lancet. (doi:10.1016/S0140-6736(13)61682-7)
33. Brown CA, Lilford RJ. 2006 The stepped wedge trial design: a systematic review. BMC Med. Res. Methodol. 6, 54. (doi:10.1186/1471-2288-6-54)
34. Swayne DE. 2009 Avian influenza vaccines and therapies for poultry. Comp. Immunol. Microbiol. Infect. Dis. 32, 351-363. (doi:10.1016/j.cimid.2008. 01.006)
35. Miller E, Salisbury D, Ramsay M. 2001 Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20(Suppl. 1), S58-67. (doi:10.1016/S0264-410X(01)00299-7)
36. Frasch CE, Preziosi MP, LaForce FM. 2012 Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM). Hum. Vaccin. Immunotherapeutics 8, 715-724. (doi:10.4161/ hv.19619)
37. Midtlyng PJ et al. 2011 Three Rs approaches in the production and quality control of fish vaccines. Biologicals 39, 117-128. (doi:10.1016/j.biologicals. 2011.02.001)
38. Reeve R, Cox S, Smitsaart E, Beascoechea CP, Haas B, Maradei E, Haydon DT, Barnett P. 2011 Reducing animal experimentation in foot-and-mouth disease vaccine potency tests. Vaccine 29, 5467-5473. (doi:10.1016/j.vaccine.2011.05.056)
39. Paton DJ, Valarcher JF, Bergmann I, Matlho OG, Zakharov VM, Palma EL, Thomson GR. 2005 Selection of foot and mouth disease vaccine strains-a review. Rev. Sci. Tech. 24, 981-993.
40. Robiolo B, La Torre J, Duffy S, Leon E, Seki C, Torres A, Mattion N. 2010 Quantitative single serumdilution liquid phase competitive blocking ELISA for the assessment of herd immunity and expected protection against foot-and-mouth disease virus in vaccinated cattle. J. Virol. Methods 166, 21-27. (doi:10.1016/j.jviromet.2010.02.011)
41. PNEFA. 2007 Assessment of the population immunity deriving from the vaccination campaigns against foot and mouth disease. Brasil.
42. WHO. 2012 Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. Report of strain selection meeting February 2012. See http://www. who.int/influenza/vaccines/virus/recommendations/ 201202_recommendation.pdf.
43. Skowronski DM et al. 2013 Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada's sentinel surveillance network, January 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles=European communicable disease bulletin, 18.
44. Brehm KE, Kumar N, Thulke HH, Haas B. 2008 High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus. Vaccine 26, 1681-1687. (doi:10. 1016/j.vaccine.2008.01.038)
45. Thakur A, Pedersen LE, Jungersen G. 2012 Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 30, 4907-4920. (doi:10.1016/j.vaccine.2012.05.049)
46. Fletcher HA. 2007 Correlates of immune protection from tuberculosis. Curr. Mol. Med. 7, 319-325. (doi:10.2174/156652407780598520)
47. Wedlock DN, Denis M, Vordermeier HM, Hewinson RG, Buddle BM. 2007 Vaccination of cattle with Danish and Pasteur strains of Mycobacterium bovis BCG induce different levels of IFNg postvaccination, but induce similar levels of protection against bovine tuberculosis. Vet. Immunol. Immunopathol. 118, 50-58. (doi:10.1016/j.vetimm. 2007.04.005)
48. Lesellier S et al. 2011 Protection of Eurasian badgers (Meles meles) from tuberculosis after intramuscular vaccination with different doses of BCG. Vaccine 29, 3782-3790. (doi:10.1016/j.vaccine. 2011.03.028)
49. Reeve R et al. 2010 Sequence-based prediction for vaccine strain selection and identification of antigenic variability in foot-and-mouth disease virus. PLoS Comput. Biol. 6, e1001027. (doi:10.1371/ journal.pcbi.1001027)
50. Shoemaker CA, Klesius PH, Drennan JD, Evans JJ. 2011 Efficacy of a modified live Flavobacterium columnare vaccine in fish. Fish Shellfish Immunol. 30, 304-308. (doi:10.1016/j.fsi.2010.11.001)
51. Cull CA, Paddock ZD, Nagaraja TG, Bello NM, Babcock AH, Renter DG. 2012 Efficacy of a vaccine and a direct-fed microbial against fecal shedding of Escherichia coli O157:H7 in a randomized pen-level field trial of commercial feedlot cattle. Vaccine 30, 6210-6215. (doi:10. 1016/j.vaccine.2012.05.080)
52. WHO. 2005 Immunization coverage cluster survey-reference manual. See http://www.who. int/vaccines-documents/DocsPDF05/www767.pdf.
53. Fine PE. 1995 Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346, 1339-1345. (doi:10.1016/S0140-6736(95)92348-9)